Merck Patent Gmbh

Ablynx N.v.

Other

Merck Patent Gesellschaft MIT Beschrankter Haftung

Merck Patent Gesellschaft MIT Beschraenkter Haftung

Bjoern Hock

Stefan Becker

Roland Kellner

Ralf Guenther

Klaus Duecker

Laura Rhiel

Denis Carniato

Johannes Gleitz

Christine G Charon

Gerald Beste

Didier Roche

Robert Hofmeister

Hilde Adi Pierrette Revets

Lars Toleikis

Christine Knuehl

Frank Kamiel Delphina Verdonck

Sigrid Godelieve Victor Cornelis

Andree Blaukat

Christina Esdar

Sophie Hallakou-Bozec

Uwe Hofmann

Christel Iffland

Qi An

Harald Kolmar

Oliver Poeschke

Gang Hao

Tanja Henzler

Mira Toister-Achituv

Vanita D Sood

Daniel Helman

Achim Doerner

Xinyan Zhao

Johannes Yeh

David Nannemann

Robin Lytle

Simon Krah

Stefan Zielonka

Christian Schroeter

Ralph Guenther

Martin Empting

Frank Kamiel Verdonck

Hilde Adi Revets

Sigrid Godelieve Cornelis

Christine Charon

The present invention relates to antibodies with specificity for FGFR1. More particularly, the invention relates to monoclonal antibodies that bind specifically to and neutralize human, macaque and mouse forms of FGFR1 with high affinity. The invention also relates to nucleic acids encoding said antibodies, vectors for expression of these nucleic acids, and host cells for producing said antibodies. Further, the invention relates to the use of said antibodies in the diagnosis and/or treatment of cancers.

Monoclonal antibody directed to FGFR1

The present invention provides a method for generating bispecific shark variable antibody domains (vNAR domains) and uses thereof. The present invention further provides fusion proteins comprising the inventive bispecific vNAR domains as well as polynucleotide libraries for use in the generation of the inventive bi-specific vNARs. Furthermore, the invention provides pharmaceutical compositions comprising the inventive bispecific vNARs or fusion proteins comprising bi-specific vNAR domains for use in the treatment of pathological conditions in an individual. The invention also provides kits of parts comprising the bispecific vNAR domains or fusion proteins.

Methods for generating bispecific shark variable antibody domains and use thereof

The present disclosure relates to amino acid sequences that are directed against (as defined herein) HER3, as well as to compounds or constructs, and in particular proteins and polypeptides, that comprise or essentially consist of one or more such amino acid sequences (also referred to herein as 'amino acid sequences of the invention', 'compounds of the invention', and &#x201c;polypeptides of the invention&#x201d;, respectively). The disclosure also relates to nucleic acids encoding such amino acid sequences and polypeptides (also referred to herein as &#x201c;nucleic acids of the invention&#x201d; or &#x201c;nucleotide sequences of the invention&#x201d;); to methods forpreparing such amino acid sequences and polypeptides; to host cells expressing or capable of expressing such amino acid sequences or polypeptides; to compositions, and in particular to pharmaceutical compositions, that comprise such amino acid sequences, polypeptides, nucleic acids and/or host cells; and to uses of such amino acid sequences or polypeptides, nucleic acids, host cells and/or compositions, in particular for prophylactic, therapeutic or diagnostic purposes, such as the prophylactic, therapeutic or diagnostic purposes mentioned herein.

Biological materials related to HER3

The present invention provides methods for the non-covalent surface display of proteins of interest (POI), in particular for Fc-domain containing proteins such as antibodies. The inventive method may be used to screen and select proteins of interest of a desired phenotype. The present invention further discloses polynucleotides and proteins and methods of producing the same, which may be used in carrying out the inventive method.

Methods for non-covalent Fc-domain-containing protein display on the surface of cells and methods of screening thereof

The invention relates to anti-TNF&#x3b1; antibodies which are engineered to exhibit a pH-sensitive antigen binding. The invention is preferably directed to anti-TNF&#x3b1; antibody adalimumab (Humira&#xae;) or biologically active variants and fragments thereof, wherein the original adalimumab antibody or variant or fragment thereof is engineered by modifications of amino acid sequence within the variable regions. Specifically, the invention relates to adalimumab or biologically active variants or fragments thereof, wherein the CDR domains are modified by replacing one or more amino acid residues by histidine residues.

Anti-TNF&#x3b1; antibodies with pH-dependent antigen binding for improved target clearence

The invention relates to a method for the production and non-covalent surface display of antibodies and derived fragments as well as molecule libraries based thereon on the surface ofcells. The non-covalent manner of the surface display renders possible the selection of specific variants by means of high throughput screening and the subsequent switchable secretion of the selected binding molecule into the culture supernatant for biochemical characterization.

Method of producing secretable antibodies by expression in saccharomyces cerevisiae

The present disclosure relates to amino acid sequences that are directed against (as defined herein) HER3, as well as to compounds or constructs, and in particular proteins and polypeptides, that comprise or essentially consist of one or more such amino acid sequences (also referred to herein as 'amino acid sequences of the invention', 'compounds of the invention', and &#x201c;polypeptides of the invention&#x201d;, respectively). The disclosure also relates to nucleic acids encoding such amino acid sequences and polypeptides (also referred to herein as &#x201c;nucleic acids of the invention&#x201d; or &#x201c;nucleotide sequences of the invention&#x201d;); to methods for 10 preparing such amino acid sequences and polypeptides; to host cells expressing or capable of expressing such amino acid sequences or polypeptides; to compositions, and in particular to pharmaceutical compositions, that comprise such amino acid sequences, polypeptides, nucleic acids and/or host cells; and to uses of such amino acid sequences or polypeptides, nucleic acids, host cells and/or compositions, in particular for prophylactic, therapeutic or diagnostic purposes, such as the prophylactic, therapeutic or diagnostic purposes mentioned herein.

Disclosed are bispecific aptamers binding with high specifity to a tumour specific antigen (TSA) and a effector cell specific antigen (ESA) for treatment of cancer.

Bispecific aptamers mediating tumour cell lysis

The present invention relates to 2-adamantylurea derivatives of formula I as selective inhibitors of the enzyme 11-beta-hydroxysteroid dehydrogenase type 1 (11&#x3b2;-HSD1) and the use of such compounds for the treatment and prevention of metabolic syndrome, diabetes, insulin resistance, obesity, lipid disorders, glaucoma, osteoporosis, cognitive disorders, anxiety, depression, immune disorders, hypertension and other diseases and conditions. 

2-adamantylurea derivatives as selective 11&#x3b2;-HSD1 inhibitors

2-adamantylurea derivatives as selective 11beta-HSD1 inhibitors

The present invention relates to methods for measuring the autophosphorylation of one or more tyrosine kinases and use of such methods in profiling kinase inhibitors and activators. As a representative example, the method comprises inducing kinase autophosphorylation activity in cells in presence and in absence of a kinase inhibitor, lysing the cells, capturing the tyrosine kinase in the cell lysate by adding a plurality of tyrosine kinase specific binding proteins which are associated with unique dyes, adding a phosphotyrosine specific antibody tagged with a marker which is distinguishable from the unique dyes, and identifying the autophosphorylated tyrosine kinase by detecting the unique dye and the marker. Alternately, the tyrosine kinases themselves could be coupled to the unique dyes. The present invention also relates to kits and compositions for carrying out the above-described methods.

Method for measuring tyrosine kinase phosphorylation

180 KDa protein histidine phosphatase interacting protein (PHPIP-180) polypeptides and polynucleotides and methods for producing such polypeptides by recombinant techniques are disclosed. Also disclosed are methods for utilizing PHPIP-180 polypeptides and polynucleotides in diagnostic assays.

180 kD protein that interacts with protein histidine phosphatase 1

PHPIP-240 polypeptides and polynucleotides and methods for producing such polypeptides by recombinant techniques are disclosed. Also disclosed are methods for utilizing PHPIP-240 polypeptides and polynucleotides in diagnostic assays.

Histidine phosphatase interacting protein with 240kD

PHPIP-120 polypeptides and polynucleotides and methods for producing such polypeptides by recombinant techniques are disclosed, also disclosed are methods for utilizing PHPIP-120 polypeptides and polynucleotides in diagnostic assays.

Histidine phosphatase interacting protein with 120kD

EphA9 polypeptides and polynucleotides and methods for producing such polypeptides by recombinant techniques are disclosed. Also disclosed are methods for utilizing EphA9 polypeptides and polynucleotides in diagnostic assays.

Human EphA9 receptor polypeptides

Growing community of inventors

Maintal, Germany

Bjoern Hock